Valence ロゴ
人気
ログイン
Loading data for PEN — first visit, this takes a few seconds.

ウォッチリストに追加

Penumbra Inc.

NYSE: PEN · リアルタイム株価 · USD
323.76
-3.08 (-0.94%)
終値時点： Aug 20, 2026, 8:00 PM
323.76
+0.00%
時間外: 4:20 PM

Penumbra Inc. (PEN) Stock Price, Analysis & Data

-0.94%

データがありません

買気配324.21
時価総額12.75B
売上高（TTM）1.5B
純利益（TTM）160.59M
ベータ0.70
EPS（TTM）4.09
PER（TTM）79.16
予想PER52.8
PBR（TTM）8.33
PSR（TTM）8.47
Earnings DateNov 4, 2026
売気配329
出来高176,392
平均出来高（20日）374,840
始値327.12
前日終値326.84
当日レンジ323.76 - 326.75
52週レンジ221.26 - 362.41
アナリストn/a
目標株価n/a
配当n/a
権利落ち日n/a

PENについて

Penumbra, Inc., together with its subsidiaries, designs, develops, manufactures, and markets medical devices in the United States and internationally. It offers computer-assisted vacuum thrombectomy; peripheral thrombectomy products, including the Indigo System for power aspiration of thrombus in the body; Lightning Flash, a mechanical thrombectomy system; Lightning Bolt 7, an arterial thrombectomy system; and CAT RX. It also provides access prod...

[続きを読む]
業種 Medical Devices
セクター Healthcare
IPO日 Sep 18, 2015
従業員数 4,700
上場取引所 NYSE
ティッカー PEN
ウェブサイト https://www.penumbrainc.com
企業情報の全文

業績

2025年のPenumbraの売上高は1.4Bで、前年の1.19Bから17.5%の増加でした。 利益は177.69Mで、1,168.11%の増加でした。

財務諸表

決算サプライズ

PenumbraはJul 30, 2026に四半期決算を発表しました：
  • 売上高は $390.05M で、予想を下回りました $0, うち 14.90% の前年比増加にあたります.
  • EPSは 1.01 で、予想を下回りました -0.17, うち 17.44% の前年比増加にあたります.

    • 次回決算発表

    Penumbra Inc.の決算発表予定日は Nov 4, 2026, 取引時間中の予定です。
    アナリストの売上高予想は ... アップグレード
    news image

    5日前 · Trefis

    Which Medtech Giant Would Buy Inspire Medical Systems?

    The market may be focused on temporary hurdles, but a strategic acquirer would see a unique technology at a strong price.

    news image

    1週間前 · Zacks

    TFX vs. PEN: Which Stock Is the Better Value Option?

    TFX vs. PEN: Which Stock Is the Better Value Option?

    news image

    2週間前 · Zacks

    Is ANGO a Buy as Med Tech Growth Battles Persistent Margin Pressure?

    AngioDynamics' Med Tech growth and reimbursement gains strengthen its outlook, but tariffs, rising costs and execution risks keep the buy case uncertain.

    news image

    3週間前 · Simply Wall St.

    Penumbra (PEN) Following THUNDERBOLT Debut, Is The Stock A Bargain Or Fairly Valued

    Penumbra (PEN) is back in focus after Novant Health reported successful use of its newly cleared THUNDERBOLT computer assisted vacuum thrombectomy system at a North Carolina comprehensive stroke cente...

    news image

    3週間前 · Simply Wall St.

    Penumbra (PEN) Wins FDA Clearance For THUNDERBOLT After Strong Stroke Study

    Penumbra (NYSE:PEN) received FDA clearance for its THUNDERBOLT computer-assisted vacuum thrombectomy system for acute ischemic stroke treatment. The THUNDER study reported strong safety and efficacy r...

    2ページ中1ページ